InfarMed has issued a circular in Portugal to remind manufacturers that CBD extracted from “cannabis for industrial purposes” is currently prohibited in Portugal. However, not all international hemp associations are in agreement with InfraMed’s interpretation, with many of them stating that the conventions do not regulate hemp and its derivatives, but only the medical markets of the substances.
InfarMed, the Portuguese ANSM, has issued a circular reminding that the use of CBD extracted from “cannabis for industrial purposes” is prohibited in Portugal.
According to the Portuguese Medicines Authority, “the inclusion of CBD or other cannabinoids, which exist naturally in the cannabis plant, is not allowed, as they are obtained by the preparation of extracts or tinctures of cannabis or its resin.”
Whether or not this is a position InfarMed or the medicines authority will maintain in the long-term is still unknown. However, if and when developments occur, it’s certain they will be covered here and in our free-to-download cannabis news app.
For Infarmed, CBD Is a Controlled Substance
Citing the Single Convention on Narcotic Drugs of 1961, Infarmed’s president, Rui Santos Ivo, states that “cosmetic products, therefore, cannot contain the following substances/preparations related to the cannabis plant, regardless of their tetrahydrocannabinol (THC) content”.
The InfarMed circular also states that “with regard to the various cannabinoids that are part of cannabis resin, and in particular the substance cannabidiol (CBD), it is the opinion of the International Narcotic Control Board (INCB) that it falls under the Single Convention on Narcotic Drugs of 1961, as an extract/preparation of the cannabis plant, and is listed in Schedule I annexed to that convention. Thus, the aforementioned substances, namely the substance cannabidiol (CBD), as cannabis resin or preparation, are included in Schedule IC, annexed to Legislative Decree No. subject to the control measures applicable to the substances therein.
InfarMed and World Hemp Associations Don’t See Eye to Eye
This is a point of view that is not shared by InfarMed and the main world hemp associations. For them, the conventions do not regulate hemp and its derivatives, but only the medical markets of the substances.
The 1971 Convention clearly underlines this principle by stating that governments “may authorize […] the use of these substances in the industry for the manufacture of non-psychotropic substances or products”.
CBD banned in cosmetics
Infarmed, therefore, highlights that the marketing of cosmetic products containing CBD is prohibited in Portugal. This regulation “prohibits the inclusion in cosmetic products of all substances listed in Schedules I and II of the Single Convention on Narcotic Drugs of 1961, through item 306 of Annex II. In addition, at the national level, these substances are considered controlled, according to the provisions of Decree-Law No. 15/93 of January 22, in its current wording.
In this sense, Infarmed states, “cosmetic products may not contain the following substances/preparations related to the cannabis plant, regardless of their tetrahydrocannabinol (THC) content:
- Cannabis and cannabis resin ;
- Cannabis extracts and tinctures;
- Leaves and flowering/flowering or fruiting tops of the cannabis plant.
Even for substances listed on CosIng, the European regulation of permitted ingredients in cosmetics, which includes by name “Cannabidiol – derived from cannabis extract or tincture or resin” or “Cannabis Sativa leaf extract”, their inclusion in cosmetic products is nevertheless prohibited.
But, for Infarmed, an ingredient listed on CosIng does not mean that its use in cosmetic products is allowed: “its inclusion in cosmetic products is not allowed”.
The circular notes that only hemp seed oil is accepted, pending a likely court case regarding the European authorization of CBD and CBG in cosmetics.
(Photo by MaxeyLash on Unsplash)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in NewsWeed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Olivia McCall is passionate about education, women and children’s rights, and the environment. A long-time investor, she covers news about the latest stocks (lately marijuana and tech), IPOs and indices, and is always on the lookout for socially responsible startups. She also writes about the food sector, and has a keen interest on cryptocurrencies.